share_log

Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target

Benzinga ·  Mar 25 10:39

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $23 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 317

Recommended

Write a comment